A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease

Abstract Background Complex medication schedules in Parkinson’s disease (PD) result in lower therapy adherence, which contributes to suboptimal therapy and clinical deterioration. Medication reminder systems might improve therapy adherence and subsequently improve symptoms of PD. This randomized con...

Full description

Bibliographic Details
Main Authors: K. Hannink, L. ter Brake, N.G.M. Oonk, A.A. Wertenbroek, M. Piek, L. Vree-Egberts, M.J. Faber, J. van der Palen, L.D. Dorresteijn
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Geriatrics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12877-019-1292-y
id doaj-c1480d7943a84428b201289e365459b5
record_format Article
spelling doaj-c1480d7943a84428b201289e365459b52020-11-25T01:40:32ZengBMCBMC Geriatrics1471-23182019-10-011911810.1186/s12877-019-1292-yA randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s diseaseK. Hannink0L. ter Brake1N.G.M. Oonk2A.A. Wertenbroek3M. Piek4L. Vree-Egberts5M.J. Faber6J. van der Palen7L.D. Dorresteijn8Department of Neurology, Medisch Spectrum TwenteDepartment of Neurology, Ziekenhuis Groep TwenteDepartment of Neurology, Medisch Spectrum TwenteDepartment of Neurology, Ziekenhuis Groep TwenteDepartment of Neurology, Medisch Spectrum TwenteDepartment of Neurology, Medisch Spectrum TwenteRadboud Institute for Health Sciences, Radboud University Medical CenterDepartment of Epidemiology, Medisch Spectrum TwenteDepartment of Neurology, Medisch Spectrum TwenteAbstract Background Complex medication schedules in Parkinson’s disease (PD) result in lower therapy adherence, which contributes to suboptimal therapy and clinical deterioration. Medication reminder systems might improve therapy adherence and subsequently improve symptoms of PD. This randomized controlled study assessed the effect of the electronic medication dispenser Medido on physical disability in PD, as a proxy for changes in therapy adherence.x Methods Eighty-seven patients were randomized into the Medido group or control group. The primary outcome of physical disability was measured by the AMC Linear Disability Scale (ALDS). Secondary outcomes were quality of life (QoL) (PDQ-39), health status (EQ5D-5L, VAS), non-motor symptoms (NMS-Quest), and QoL of the caregiver (PDQ-carer). Measurements were performed at baseline, and after 3 and 6 months follow-up. Results When using the Medido, a non-significant improvement of 3.0 points (95% CI -5.6;11.6) was seen in ALDS. The exploratory subgroup Hoehn & Yahr classification (H&Y) > 2.5 improved significantly on ALDS with 14.7 points (95% CI -28.5;-0.9, p = 0.029 for group x time interaction). QoL deteriorated with 1.0 point in PDQ-39 (p = 0.01 for group x time interaction) in favor of the control group. Non-significant differences were observed for VAS (0.4 points, p = 0.057) and NMS-Quest (1.3 points, p = 0.095) in favor of the Medido group. No changes over time were observed in EQ5D-5L and PDQ-carer. Conclusions Based on these data, no firm conclusion can be drawn, but use of the Medido medication dispenser may result in a clinical improvement of physical disability and seems particularly appropriate for more severe patients. Trial registration NTR3917. Registered 19 March 2013.http://link.springer.com/article/10.1186/s12877-019-1292-yParkinson’s diseaseElectronic medication dispenserTherapy adherencePhysical disabilityQuality of life
collection DOAJ
language English
format Article
sources DOAJ
author K. Hannink
L. ter Brake
N.G.M. Oonk
A.A. Wertenbroek
M. Piek
L. Vree-Egberts
M.J. Faber
J. van der Palen
L.D. Dorresteijn
spellingShingle K. Hannink
L. ter Brake
N.G.M. Oonk
A.A. Wertenbroek
M. Piek
L. Vree-Egberts
M.J. Faber
J. van der Palen
L.D. Dorresteijn
A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
BMC Geriatrics
Parkinson’s disease
Electronic medication dispenser
Therapy adherence
Physical disability
Quality of life
author_facet K. Hannink
L. ter Brake
N.G.M. Oonk
A.A. Wertenbroek
M. Piek
L. Vree-Egberts
M.J. Faber
J. van der Palen
L.D. Dorresteijn
author_sort K. Hannink
title A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
title_short A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
title_full A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
title_fullStr A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
title_full_unstemmed A randomized controlled efficacy study of the Medido medication dispenser in Parkinson’s disease
title_sort randomized controlled efficacy study of the medido medication dispenser in parkinson’s disease
publisher BMC
series BMC Geriatrics
issn 1471-2318
publishDate 2019-10-01
description Abstract Background Complex medication schedules in Parkinson’s disease (PD) result in lower therapy adherence, which contributes to suboptimal therapy and clinical deterioration. Medication reminder systems might improve therapy adherence and subsequently improve symptoms of PD. This randomized controlled study assessed the effect of the electronic medication dispenser Medido on physical disability in PD, as a proxy for changes in therapy adherence.x Methods Eighty-seven patients were randomized into the Medido group or control group. The primary outcome of physical disability was measured by the AMC Linear Disability Scale (ALDS). Secondary outcomes were quality of life (QoL) (PDQ-39), health status (EQ5D-5L, VAS), non-motor symptoms (NMS-Quest), and QoL of the caregiver (PDQ-carer). Measurements were performed at baseline, and after 3 and 6 months follow-up. Results When using the Medido, a non-significant improvement of 3.0 points (95% CI -5.6;11.6) was seen in ALDS. The exploratory subgroup Hoehn & Yahr classification (H&Y) > 2.5 improved significantly on ALDS with 14.7 points (95% CI -28.5;-0.9, p = 0.029 for group x time interaction). QoL deteriorated with 1.0 point in PDQ-39 (p = 0.01 for group x time interaction) in favor of the control group. Non-significant differences were observed for VAS (0.4 points, p = 0.057) and NMS-Quest (1.3 points, p = 0.095) in favor of the Medido group. No changes over time were observed in EQ5D-5L and PDQ-carer. Conclusions Based on these data, no firm conclusion can be drawn, but use of the Medido medication dispenser may result in a clinical improvement of physical disability and seems particularly appropriate for more severe patients. Trial registration NTR3917. Registered 19 March 2013.
topic Parkinson’s disease
Electronic medication dispenser
Therapy adherence
Physical disability
Quality of life
url http://link.springer.com/article/10.1186/s12877-019-1292-y
work_keys_str_mv AT khannink arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lterbrake arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT ngmoonk arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT aawertenbroek arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT mpiek arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lvreeegberts arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT mjfaber arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT jvanderpalen arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lddorresteijn arandomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT khannink randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lterbrake randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT ngmoonk randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT aawertenbroek randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT mpiek randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lvreeegberts randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT mjfaber randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT jvanderpalen randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
AT lddorresteijn randomizedcontrolledefficacystudyofthemedidomedicationdispenserinparkinsonsdisease
_version_ 1725045184172916736